ImmunoPeCa and MOC31PE

Acredit members Ida Storhaug Fr√łysnes, Yvonne Andersson, Svein Dueland and Kjersti Flatmark have published a paper outlining work completed that looked into the safety and toxicity of the immunotoxin MOC31PE. The ImmunoPeCa trial investigated the use of intraperitoneal MOC31PE in patients undergoing CRS-HIPEC surgery with mitomycin C for peritoneal metastases from colorectal cancer (PM-CRC). Results indicate that there is a bright future for research into the use of immunotoxins for the treatment of PM-CRC.

To read Yvonne and Kjersti’s paper, please click here.